Coya Therapeutics licenses Dr. Reddy's Abatacept for COYA 302 development

Coya will pay a one-time non-refundable upfront fee to Dr Reddy's, and will also owe tiered milestone payments to the company

Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.